Drug recall · April 22, 2026
Bupivacaine Hydrochloride 0.75% in 8.25% Dextrose Injection recall
Why: Lack of Assurance of Sterility
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Bupivacaine Hydrochloride 0.75% in 8.25% Dextrose Injection, USP (15 mg/2 mL) (7.5 mg/mL) ampules, Rx only, Manufactured by: Houns Co., Ltd, 100, Bio valley, Je-cheor-Si, Chungcheongbuk-dc, Korea, NDC 73293-0002-1 (2 mL ampule), NDC 73293-0002-2 (50 x 2 Single-dose ampules); Distributed: Brookfield Pharmaceuticals, LLC, Brookfield, WI 53005, Made in S. Korea, NDC 71351-022-02 (ampule), NDC 71351-022-10 (10 count ampules), NDC 71351-022-50 (50 count ampules)
- Lots / codes
All lots within expiry
- Quantity
- 3,260,170 ampules
- Company
- Huons Co., Ltd., Jecheon, N/A
- Distribution
- USA Nationwide.
- Initiated
- April 2, 2026 · Voluntary: Firm initiated
- Classified
- May 15, 2026
- Reported
- April 22, 2026
- How notified
- N/A
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bupivacaine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.